Navigation Links
Amarantus BioScience Launches New Website
Date:1/28/2013

d MANF, and is initially focusing on the development of MANF-based protein therapeutics.  MANF's current lead indication is Parkinson's disease with additional focus on Traumatic Brain Injury (TBI.  Future indications may include myocardial infarction and certain rare and ultra-rare orphan diseases where MANF is currently being evaluated.  

The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line, and it is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company's inventory of PhenoGuard Cell Lines.

About Amarantus BioScience, Inc.

Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com. To follow the Company, please sign-up for email alerts, and follow the Company on Twitter and Facebook.

Forward Looking Statements

<
'/>"/>
SOURCE Amarantus BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amarantus Bioscience Launches Online Corporate Communication Channels
2. Amarantus Bioscience to Present at OneMedForum 2013
3. Amarantus Appoints Super Bowl Champion Toi Cook to Board of Advisors to Advance TBI Program
4. Amarantus Completes Name Change and CUSIP Change
5. Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinsons Disease
6. Amarantus BioSciences Demands Cessation of Unauthorized Listing on Berlin-Bremen Stock Exchange
7. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
8. Amarantus BioSciences Wins MANF Patent Challenge in Europe
9. Amarantus BioSciences Issues CEO Letter to Shareholders
10. Amarantus BioSciences Secures $1.1 Million in Financing
11. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... ... June 26, 2015 , ... Charm Sciences, Inc. ... Packers and Stockyards Administration (GIPSA) awarded a five year contract to Charm Sciences ... utilizing Charm’s ROSA DONQ-FAST5 Test. This 5 minute quantitative test extracts DON from ...
(Date:6/26/2015)... , June 23, 2015 ... the addition of the "Global Cancer Biosimilars ... Market introduction of cancer biosimilar is ... commercialization potential. Chemotherapeutic drugs have dominated the cancer ... have been introduced in past few years. They ...
(Date:6/25/2015)... Last June, a dedicated global team of Ebola ... large-scale genome sequencing. Their research, which was written on the ... Cell (Park 2015) , reveals critical information ... of the recent Ebola outbreak. Today Authorea is ... and full edit history of the paper are available ...
(Date:6/25/2015)... ... June 25, 2015 , ... Students entering the ... new chemistry laboratories, each exclusively using filtered fume hoods that feature Erlab’s ... (49) filtered fume hoods needed for their Organic, Inorganic, Analytical, and Physical Chemistry ...
Breaking Biology Technology:USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2Global Cancer Biosimilars Market Opportunity Outlook 2Global Cancer Biosimilars Market Opportunity Outlook 3Open Science Takes Major Leap Forward 2This Summer Erlab Completes the Largest Installation of Filtered Fume Hoods in the World 2
... 5-Year Survival Data for Responding Patients, BERKELEY ... Board: GNTA) announced that the Company has,submitted an ... for its,New Drug Application (NDA) for Genasense(R) (oblimersen ... refractory chronic,lymphocytic leukemia (CLL). The submission is based ...
... CHICAGO, June 5 "AHIMA,s Board of Directors ... strengthen the effort,to address health IT from a strategic ... executives. In addressing the need to,realize real benefits from ... AHIMA will continue working to support the NAHIT,mission and ...
... June 5 BioTrends Research Group, Inc. is,pleased ... II. The report is based on the results ... in the UK, France, Germany, Italy, and Spain.,The ... hyperphosphatemia,and secondary hyperparathyroidism., In the ESA market, ...
Cached Biology Technology:Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 2Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 3Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 4New Study by BioTrends Highlights Practice Management Shifts Among European Nephrologists 2
(Date:6/25/2015)... June 25, 2015  Imagine a tool specifically designed ... healthier, happier life. That,s exactly what USANA,s True ... The cutting-edge, portable health program provides a personalized approached ... help improve your lifestyle and nutrition. ... gala Wednesday night, USANA,s THA was honored with the ...
(Date:6/24/2015)... , June 22, 2015 ... announced the addition of the "Huawei Ascend ... report to their offering. Huawei,s ... to the opposite direction than Apple,s and Samsung,s ... fingerprint sensor developed by Fingerprint Cards, a main ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... Lee Lovering, Ph.D., School of Biosciences, University of ... Award for his seminal work on the structural ... and modify cell walls in bacteria. Natalie Strynadka, ... Lovering,s work: "his spectacular abilities in structural biology ...
... 2012) Aeras and the Infectious Disease Research Institute ... trial of IDRI,s novel tuberculosis vaccine candidate, ID93 + ... safety, tolerability and immunogenicity of the vaccine candidate in ... by Johnson County Clin-Trials in Lenexa, Kansas, in close ...
... risks posed to people who work with tiny fibres used ... Research into the health risks posed by nanofibres ... has pinpointed the lengths at which these fibres are ... from a range of materials including carbon, are about 1,000 ...
Cached Biology News:The American Society for Microbiology honors Andrew Lovering 2As TB grows more difficult to control, vaccine candidate to prevent disease enters clinical testing 2
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
Bis-Acrylamide (bis) is a monomer used as a crosslinker with acrylamide to form polyacrylamide electrophoretic gels. This 2% bis solution is supplied as 500 ml....
Anti-human VEGFR-2/KDR (Protein-A Purified) Polyclonal Antibody...
Mouse monoclonal antibody to Lats2....
Biology Products: